Pre filled syringes 2014-2024

24
©notice This material is copyright by visiongain. It is against the law to reproduce any of this material without the prior written agreement of vision- gain. You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each pur- chase and single copy is for personal use only. Pre-Filled Syringes: World Industry and Market Prospects 2014-2024

description

For more information on this report please contact [email protected] (+44 (0) 2075499976) or refer to our website http://www.visiongain.com/Report/1149/Pre-Filled-Syringes-World-Industry-and-Market-Prospects-2014-2024

Transcript of Pre filled syringes 2014-2024

Page 1: Pre filled syringes 2014-2024

©noticeThis material is copyright by visiongain. It is against the law to reproduce any of this material without the prior written agreement of vision-gain. You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each pur-chase and single copy is for personal use only.

Pre-Filled Syringes: World Industry and Market Prospects 2014-2024

Page 2: Pre filled syringes 2014-2024

www.visiongain.com

Contents

1.1 Pre-Filled Syringes: World Market Outlook 2014-2024

1.2 Report Contents

1.2.1 Benefits of this Report

1.3 Report Methodology

1.3.1 Who is this Report for?

1.3.2 Defining the Pre-Filled Syringe Market

2.1 A Brief History of Pre-Filled Syringes

2.2 Design and Manufacture of Pre-Filled Syringes

2.2.1 Glass and Plastic Syringes

2.2.2 Safety and the Pre-Filled Syringe Market

2.2.2.1 Concerns over Needlestick Injuries

2.3 An Introduction to Pen Injectors and Autoinjectors

2.3.1 Pen Injectors and Autoinjectors Offer Advantages in Self-Administration

2.3.2 What Determines Injection Device Choice?

2.4 Future Directions for Pre-Filled Syringes

3.1 The World Pre-Filled Syringe Market 2012-2013

3.1.1 Rapid Growth in Demand and Revenues in the Last Decade

3.1.2 Pre-Filled Syringes as a Share of the Global Drug Delivery Market

3.1.3 Pre-Filled Syringe Market Breakdown by Device 2012

3.2 Growth in the Pre-Filled Syringe Market 2014-2024

3.2.1 Pre-Filled Syringe Market Forecast 2014-2024

1. Executive Summary

2. An Introduction to the Pre-Filled Syringe Market

3. Pre-Filled Syringes: World Market Outlook and Forecast 2014-2024

Page 3: Pre filled syringes 2014-2024

www.visiongain.com

Contents 3.2.2 Pre-Filled Syringe Unit Sales Forecast 2014-2024

3.2.3 Biologics and Other Market Drivers for this Decade

3.2.3.1 Market Genericisation and Pre-Filled Syringes

3.2.3.2 The Injectable Drug Pipeline is Long

3.2.4 What Will Restrain Market Growth to 2024?

3.2.5 Leading Submarket Revenue Shares 2014-2024

3.3 The Glass Pre-Filled Syringe Submarket 2014-2024

3.3.1 Steady Growth for the Glass Pre-Filled Syringe Submarket 2014-2024

3.3.2 New Manufacturing Processes to Drive Submarket Growth to 2024

3.4 The Plastic Pre-Filled Syringe Submarket 2014-2024

3.4.1 Rapid Growth Forecast for the Plastic Pre-Filled Syringe Submarket to 2024

3.4.2 Plastic Pre-Filled Syringe Submarket Drivers and Restraints 2014-2024

3.5 The Pen Injector and Autoinjector Submarket 2014-2024

3.5.1 Growth in the Pen Injector and Autoinjector Submarket to 2024

3.5.2 High Demand for Simplified Self-Administration Devices

3.5.3 Insulin and Other Biologics to Lead Market Growth

4.1 Leading National Markets for Pre-Filled Syringes 2012-2013

4.2 National Pre-Filled Syringe Market Forecasts 2014-2024

4.2.1 How Will National Market Shares Change to 2024?

4.3 The US Pre-Filled Syringe Market Forecast 2014-2024

4.3.1 New Drug and Device Launches to Drive Growth to 2024

4.4 Leading EU Nations: National Pre-Filled Syringe Submarket Forecasts 2014-2024

4.4.1 Biosimilars and Growth in the EU Pre-Filled Syringe Submarket 2014-2024

4.5 Pre-Filled Syringes in Japan: Market Outlook and Forecast 2014-2024

4.6 Pre-Filled Syringes in Emerging Markets 2014-2024

4.6.1 Pre-Filled Syringe Manufacturers Are Investing in Emerging Markets

4.6.2 China: The Leading Emerging Pre-Filled Syringe Submarket 2014-2024

4. Leading National Markets for Pre-Filled Syringes 2014-2024

Page 4: Pre filled syringes 2014-2024

www.visiongain.com

Contents 4.6.3 India: Double-Digit Growth Forecast 2014-2024

4.6.4 Brazil: Biologics Growth to Lead to Higher Demand for Pre-Filled Syringes 2014-2024

4.6.5 Russia: Submarket Forecast 2014-2024

5.1 Leading Therapeutic Sectors for Pre-Filled Syringes and Other Injection Devices 2012-2013

5.1.1 Vaccines and Heparins Are Major Market Sectors 2012-2013

5.1.2 Rising Demand in Chronic Conditions: Autoimmune Diseases and Diabetes

5.1.3 Growth for Key Market Sectors 2014-2024

5.2 Pre-Filled Syringes and Pen Injectors for Diabetes 2014-2024

5.2.1 Insulin Market Forecast 2014-2024

5.2.2 High Rates of Pen Injector Use in the EU and Japan

5.2.3 Insulin Pumps: A Technology to Challenge Pen Injectors to 2024?

5.2.4 The Prospects for Biosimilar Insulin in Developed and Emerging Markets

5.2.4.1 Injection Devices for Biosimilar Insulin Products

5.3 Rheumatoid Arthritis: Leading Biologics Dominate the Market 2013

5.3.1 Rheumatoid Arthritis Market Forecast 2014-2024

5.3.2 All Major Injectable Therapies Are Marketed in Proprietary Devices

5.3.3 Novel Injection Systems for RA: Meeting the Needs of Patients

5.3.4 The Threat from Oral Therapies to 2024

5.4 Self-Injection for Multiple Sclerosis: Outlook 2014-2024

5.4.1 Multiple Sclerosis Market Forecast 2014-2024

5.4.2 Reusable Autoinjectors for Interferon Beta Therapy

5.4.3 Oral Therapies to Drive MS Market Growth in this Decade

5.5 Growth Hormones Market Outlook and Forecast 2014-2024

5.5.1 Growth Hormone Market Forecast 2014-2024

5.5.2 Biosimilar Growth Hormones and Pen Injectors

5.5.3 Uptake of Needle-Free Injectors for Growth Hormone Administration

5. Outlook for Leading Therapeutic Sectors for Pre-Filled Syringes 2014-2024

Page 5: Pre filled syringes 2014-2024

www.visiongain.com

Contents 5.6 Pre-Filled Heparin Syringes 2014-2024

5.6.1 One Brand Leads the Heparin Market, 2012-2013

5.6.2 Pre-Filled Syringes for LMWHs

5.6.3 Heparin Market Forecast 2014-2024

5.6.4 Follow-On Heparins: Biosimilars or Generics?

5.7 The Vaccine Market Outlook 2014-2024

5.7.1 Vaccine Market Forecast 2014-2024

5.7.2 Single-Use Devices for Vaccine Delivery

5.7.2.1 BD Uniject: A Private-Public Collaboration

5.7.3 Needle-Free Injectors for Vaccines

6.1 Leading Insulin Therapies Using Pen Injectors 2014-2024

6.1.1 Lantus: The World’s Bestselling Insulin Analogue

6.1.1.1 SoloSTAR, ClikSTAR and AllSTAR: Three Pen Injectors for Lantus

6.1.1.2 Outlook for Lantus 2014-2024

6.1.2 NovoLog: The Leading Fast-Acting Insulin

6.1.2.1 NovoLog FlexPen: Room Temperature Storage for Patient Convenience

6.1.2.2 Faster-Acting Insulin in Development

6.1.3 Humalog

6.1.3.1 Humalog: HumaPen and KwikPen

6.1.3.2 Humalog Revenue Forecast 2014-2024

6.2 Top Biologics for Rheumatoid Arthritis: Device Outlook to 2024

6.2.1 Humira: The Biggest Selling Drug in 2012

6.2.1.1 The Humira Pen Is an Innovative Delivery Device

6.2.1.2 Steady Revenue Growth for Humira to 2017

6.2.2 Enbrel

6.2.2.1 Pre-Filled Injection Devices Available for Enbrel 2013

6.2.2.2 Protected from Biosimilars for this Decade?

6. Leading Pre-Filled Device Therapies 2014-2024

Page 6: Pre filled syringes 2014-2024

www.visiongain.com

Contents 6.3 Multiple Sclerosis: Leading Injectable Therapies 2014-2024

6.3.1 Copaxone: An Injectable Non-Interferon Therapy

6.3.1.1 Copaxone Uses the Autoject 2 Autoinjector from Owen Mumford

6.3.1.2 Next-Generation Copaxone and Generics Expected in 2014

6.3.2 Avonex

6.3.2.1 Biogen Idec Launches the Avonex Pen 2011

6.3.2.2 Outlook for Avonex 2014-2024

6.3.3 Rebif

6.3.3.1 Self-Injection Options for Rebif: Rebiject II, RebiSmart and RebiDose

6.3.3.2 Rebif: A Similar Outlook to Avonex to 2024?

6.4 Two Growth Hormones Dominate the Market 2013

6.4.1 Norditropin: Outlook 2014-2024

6.4.2 Genotropin: Outlook and Revenue Forecast 2014-2024

6.5 Outlook for Leading Heparin Products 2014-2024

6.5.1 Lovenox: Generic Competition in the US Since 2010

6.5.1.1 Lovenox: Revenue Forecast 2014-2024

6.5.2 Arixtra and Fragmin

7.1 Pre-Filled Syringes Market: Strengths and Weaknesses 2012-2013

7.1.1 Pre-Filled Syringes Offer Many Benefits Over Other injection Technologies

7.2 Pre-Filled Syringes Market: Opportunities and Threats 2014-2024

7.2.1 Pre-Filled Syringes Face Challenges from Other Technologies

7.3 Pre-Filled Syringes Market: STEP Analysis 2014-2024

7.3.1 Social Factors: Rising Disease Incidence and Demand for At-Home Care

7.3.2 Technological Developments: Improved Safety and Administration

7.3.3 Economic Pressures: Pre-Filled Syringes Are Cost Efficient

7.3.3.1 High Barriers to Market Entry Exist

7.3.4 Political Issues: Regulatory Developments for Pre-Filled Syringes

7. Pre-Filled Syringes: Industry Trends 2014-2024

Page 7: Pre filled syringes 2014-2024

www.visiongain.com

Contents 7.4 Regulatory and Safety Outlook for Pre-Filled Syringes 2014-2024

7.4.1 Needlestick Safety and Prevention

7.4.2 International Regulations for Needlestick Prevention

7.4.2.1 The US: The First Country to Introduce Needlestick Legislation

7.4.2.2 The EU: New Rules from 2013 Onwards

7.4.2.3 Needlestick Safety in Japan 2014-2024

7.4.2.4 Legislation for Needlestick Safety in Emerging Markets

7.4.3 Manufacturers Will Continue to Develop New Devices for Needlestick Prevention

7.4.3.1 Ancillary versus Integrated Safety Devices

7.4.4 Extractables and Leachables

7.4.4.1 Companies Will Reduce Sources of Extractables and Leachables

7.4.5 Products that Minimise Extractables and Leachables

7.4.5.1 Protein Aggregation: The Challenge of Biological Drugs

7.4.5.2 Regulatory Requirements for Extractables and Leachables 2013

7.5 Biologics and the Pre-Filled Syringes Market 2014-2024

7.5.1 Manufacturing Pre-Filled Syringes for Biologics: Glass versus Plastic

7.5.2 Biologics Provide New Challenges for Device Manufacturers

7.5.2.1 Lyophilised Drugs and Dual-Chamber Devices

7.5.3 Delivery Opportunities for High Viscosity Drugs

7.5.4 Are Biosimilars an Opportunity for Pre-Filled Syringe Manufacturers?

7.6 The Role of Patients in Pre-Filled Syringe Industry Development and Growth

7.6.1 Chronic Disease Incidence 2014-2024

7.6.2 The Rise in At-Home Care

7.6.3 Improving Patient Adherence

7.6.4 Injection Devices Must be Developed for Patient Convenience: Human Factor

Engineering

7.7 Technological Developments in Pre-Filled Syringes to 2024

7.7.1 Product Differentiation Will be Vital in Crowded Treatment Markets

7.7.1.1 Product Customisation: Adapting Injection Devices

7.7.2 Trends in Manufacturing Materials for Pre-Filled Syringes

Page 8: Pre filled syringes 2014-2024

www.visiongain.com

Contents 7.7.3 Competing Technologies Will Challenge Pre-Filled Syringes

7.7.3.1 Will Needle-Free Devices Become a Significant Competing Technology?

7.7.3.2 Patients Prefer Oral Drug Delivery

7.8 Outsourcing in the Pre-Filled Syringe Industry

7.8.1 Contract Medical Device Manufacturing

7.8.2 Contract Filling of Pre-Filled Syringes

8.1 Leading Pre-Filled Syringe Manufacturers 2013

8.1.1 BD Is the Clear Market Leader

8.1.1.1 New Product Launches 2013

8.1.1.2 Outlook for BD’s Pre-Filled Syringes 2014-2024

8.1.2 Gerresheimer: Glass and Plastic Syringes and Pen Injectors

8.1.2.1 Gerresheimer: Recent Performance and Outlook

8.1.3 Schott

8.1.3.1 Schott Reports Rising Demand for Plastic Syringes

8.1.4 Nipro Is a Market Leader through its MGlas Acquisition

8.1.5 Nuova Ompi

8.1.5.1 Expansion Planned to 2016

8.1.6 Emerging Market Players

8.1.6.1 Weigao: Pre-Filled Syringes for China and Beyond

8.1.6.2 Unilife: Pre-Filled Safety Syringes

8.1.6.3 Roselabs Entered the Market in 2012

8.2 Leading Pen Injector and Autoinjector Manufacturers 2013

8.2.1 SHL Group

8.2.1.1 Growth for SHL Group 2014-2024

8.2.2 Ypsomed

8.2.2.1 Pen Injector Revenue Returning to Growth in 2014

8. Leading Pre-Filled Syringe and Related Technology Manufacturers 2013

Page 9: Pre filled syringes 2014-2024

www.visiongain.com

Contents 8.2.3 Haselmeier

8.2.3.1 Haselmeier Is Looking to Expand Globally

8.2.4 Owen Mumford

8.2.4.1 Outlook for Owen Mumford 2014-2024

8.2.5 Other Leading and Emerging Autoinjector Manufacturers

8.3 Leading Pre-Filled Syringe Component Manufacturers 2013

8.3.1 Datwyler

8.3.1.1 Datwyler: Growth Prospects 2014-2024

8.3.2 West Pharmaceutical Services

8.3.2.1 Expanding Manufacturing in Emerging Markets

9.1 Richard Harrison, Business Development Manager, Injectables, Bespak Europe

9.1.1 Bespak

9.1.2 Unmet Needs and Future Directions for Autoinjectors

9.1.3 Challenges in Developing Autoinjectors

9.1.4 Trends from Drug Development Impacting Device Manufacturers

9.2 David Daily, Director R&D and BD, Injectable Delivery Devices, Elcam Medical and CEO, DALI

Medical Devices

9.2.1 Elcam Medical

9.2.2 Key Unmet Needs and Challenges for Pre-Filled Syringes and Autoinjectors

9.2.3 Advantages of Pre-Filled Syringes over Other Modes of Drug Delivery

9.2.4 Growth in the Pre-Filled Syringe Market to 2024

9.3 West Pharmaceutical Services

9.3.1 Changes in Demand for Pre-Filled Syringes

9.3.2 Future Expectations for the Pre-Filled Syringe Market

9.3.3 The Role of Emerging Markets in Pre-Filled Syringe Growth

9.3.4 Drug Development Trends Impacting Device Manufacturers to 2024

9. Expert Opinion

Page 10: Pre filled syringes 2014-2024

www.visiongain.com

Contents

10.1 Pre-Filled Syringe Market Overview 2012-2013

10.1.1 Glass Syringes Dominate in 2013

10.2 Pre-Filled Syringe Market Growth 2014-2024

10.2.1 Commercial Drivers for Pre-Filled Syringes

10.3 The Future of Pre-Filled Injection Devices

10. Conclusions from our Study

Page 11: Pre filled syringes 2014-2024

www.visiongain.com

Contents

Table 1.1 Currency Exchange Rates

Table 3.1 Pre-Filled Syringe Market: Revenue ($bn) and Units (bn), 2012-2013

Table 3.2 Pre-Filled Syringe Market by Sector: Revenue ($bn) and Units (bn), 2012

Table 3.3 Pre-Filled Syringe Market: Overall Market and Revenue Forecasts ($bn) by Sector,

2012-2024

Table 3.4 Pre-Filled Syringe Market: Overall Market Unit Forecasts (bn) by Sector, 2012-2024

Table 3.5 Pre-Filled Syringe Market Revenue: Submarket Shares (%), 2012-2024

Table 3.6 Glass Pre-Filled Syringe Submarket: Revenue Forecast ($bn), 2012-2024

Table 3.7 Selected Proprietary Polymers for Plastic Pre-Filled Syringes, 2013

Table 3.8 Plastic Pre-Filled Syringe Submarket: Revenue Forecast ($bn), 2012-2024

Table 3.9 Pen Injector and Autoinjector Submarket: Revenue Forecast ($bn), 2012-2024

Table 4.1 Pre-Filled Syringe Market: Revenues ($bn) by Country, 2012-2013

Table 4.2 Pre-Filled Syringe Market: Regional and National Submarket Revenue Forecasts ($bn),

2012-2024

Table 4.3 Pre-Filled Syringe Market: National Submarket Shares (%)

Table 4.4 US Pre-Filled Syringe Submarket Forecast ($bn), 2012-2024

Table 4.5 European Pre-Filled Syringe Market: Leading National Submarket Revenue Forecasts

($bn), 2012-2024

Table 4.6 Japanese Pre-Filled Syringe Submarket Forecast ($bn), 2012-2024

Table 4.7 Chinese Pre-Filled Syringe Submarket Forecast ($bn), 2012-2024

Table 4.8 Indian Pre-Filled Syringe Submarket Forecast ($bn), 2012-2024

Table 4.9 Brazilian Pre-Filled Syringe Submarket Forecast ($bn), 2012-2024

Table 4.10 Russian Pre-Filled Syringe Submarket Forecast ($bn), 2012-2024

Table 5.1 Pen Manufacturing Agreements for Leading Insulin Brand Manufacturers, 2013

Table 5.2 Selected Biosimilar Insulin Pen Injectors, 2013

Table 5.3 Insulin Market: Revenue Forecast ($bn), 2012-2024

Table 5.4 Rheumatoid Arthritis Market: Revenue Forecast ($bn), 2012-2024

List of Tables

Page 12: Pre filled syringes 2014-2024

www.visiongain.com

Contents Table 5.5 Interferon Beta Therapies for MS, 2013

Table 5.6 Oral Therapies Launched for MS, 2010-2013

Table 5.7 Multiple Sclerosis Market: Revenue Forecast ($bn), 2012-2024

Table 5.8 Growth Hormone Market: Revenue Forecast ($bn), 2012-2024

Table 5.9 Selected Emerging Market Biosimilar Growth Hormones, 2013

Table 5.10 Heparin Market: Revenue Forecast ($bn), 2012-2024

Table 5.11 Vaccine Market by Company: Revenues ($bn), 2012

Table 5.12 Vaccines Market: Revenue Forecast ($bn), 2012-2024

Table 6.1 Leading Pre-Filled Insulin Therapies: Revenues ($bn), 2008-2012

Table 6.2 Lantus: Revenue Forecast ($bn), 2012-2024

Table 6.3 NovoLog: Revenue Forecast ($bn), 2012-2024

Table 6.4 Humalog: Revenue Forecast ($bn), 2012-2024

Table 6.5 Leading Pre-Filled Rheumatoid Arthritis Therapies: Revenues ($bn), 2010-2012

Table 6.6 Humira: Revenue Forecast ($bn), 2012-2024

Table 6.7 Enbrel: Revenue Forecast ($bn), 2012-2024

Table 6.8 Leading Pre-Filled Multiple Sclerosis Therapies: Revenues ($bn), 2008-2012

Table 6.9 Copaxone: Revenue Forecast ($bn), 2012-2024

Table 6.10 Avonex: Revenue Forecast ($bn), 2012-2024

Table 6.11 Rebif: Revenue Forecast ($bn), 2012-2024

Table 6.12 Leading Pre-Filled Growth Hormone Therapies: Revenues ($bn), 2010-2012

Table 6.13 Norditropin: Revenue Forecast ($bn), 2012-2024

Table 6.14 Genotropin: Revenue Forecast ($bn), 2012-2024

Table 6.15 Leading Pre-Filled Heparins: Revenues ($bn), 2010-2012

Table 6.16 Lovenox: Revenue Forecast ($bn), 2012-2024

Table 7.1 Pre-Filled Syringe Market: Strengths and Weaknesses, 2012-2013

Table 7.2 Benefits and Weaknesses to Pre-Filled Syringes as an Injectable Delivery Device, 2013

Table 7.3 Pre-Filled Syringe Market: Opportunities and Threats, 2014-2024

Table 7.4 Pre-Filled Syringe Market: STEP Analysis, 2014-2024

Table 7.5 Leading Market Participants: Broad Product Portfolios, 2013

Table 7.6 Hepatitis B and C: Prevalence by Country, 2013

Page 13: Pre filled syringes 2014-2024

www.visiongain.com

Contents Table 7.7 Selected Safety Products for Pre-Filled Syringes, 2013

Table 7.8 Selected Pre-Filled Injection Devices for Lyophilised Drugs, 2013

Table 7.9 Leading Blockbuster Biologic Patent Expiries in the US and EU, 2013-2028

Table 7.10 Pre-Filled Syringe Manufacturers: Alternative Injectable Technologies, 2013

Table 7.11 Selected Insulin Pumps Available, 2013

Table 7.12 Oral Drug Competitors for Leading Pre-Filled Syringe Therapeutic Sectors, 2014-2024

Table 7.13 Selected Leading CMOs: Pre-Filled Syringe Filling Capabilities, 2013

Table 8.1 BD: Pre-Filled Injection Systems, 2013

Table 8.2 BD Medical - Pharmaceutical Systems: Revenue ($bn), 2008-2012

Table 8.3 Gerresheimer: Revenue ($bn) by Division, 2010-2012

Table 8.4 Schott: Revenue ($bn), 2011-2012

Table 8.5 Weigao: Pre-Filled Syringe Revenue ($m) and Production Volume, 2010-2012

Table 8.6 Unilife: Pre-Filled Syringe Product Portfolio, 2013

Table 8.7 Unilife: Revenue ($m), 2008-2013

Table 8.8 SHL Group: Pen Injector and Autoinjector Portfolio, 2013

Table 8.9 Ypsomed: Pen Injector and Autoinjector Portfolio, 2013

Table 8.10 Ypsomed Delivery Devices: Revenue ($bn), 2009-2013

Table 8.11 Haselmeier: Pen Injector and Autoinjector Portfolio, 2013

Table 8.12 Owen Mumford: Pen Injector and Autoinjector Portfolio, 2013

Table 8.13 Owen Mumford: Revenue ($bn), 2009-2012

Table 8.14 Datwyler Pharma Packaging: Revenue ($bn), 2007-2012

Table 8.15 West Pharmaceutical Services: Revenue ($bn) by Division, 2009-2012

Table 9.1 Bespak: Needle-Free Injectors, 2013

Table 10.1 Pre-Filled Syringe Market: Revenue Forecasts ($bn) and Market Shares (%) by Sector,

2012-2024

Table 10.2 Pre-Filled Syringe Market: Revenue Forecasts ($bn) and Market Shares (%) by

Region, 2012-2024

Page 14: Pre filled syringes 2014-2024

www.visiongain.com

Contents

Figure 2.1 Key Events in the Pre-Filled Syringe Market History, 1954-2000

Figure 2.2 Major Trends for Pre-Filled Syringe Market Growth, 2014-2024

Figure 3.1 Pre-Filled Syringe Market: Revenue ($bn) and Units (bn), 2012-2013

Figure 3.2 Pre-Filled Syringe Market: Revenue Share (%) by Sector, 2012

Figure 3.3 Pre-Filled Syringe Market: Unit Share (%) by Sector, 2012

Figure 3.4 Pre-Filled Syringe Market Forecast ($bn), 2012-2024

Figure 3.5 Pre-Filled Syringe Market Unit Forecast (bn), 2012-2024

Figure 3.6 Pre-Filled Syringe Unit Share (%) by Sector, 2012-2024

Figure 3.7 Pre-Filled Syringes Market: Drivers, 2014-2024

Figure 3.8 Pre-Filled Syringes Market: Restraints, 2014-2024

Figure 3.9 Pre-Filled Syringe Market Revenue: Submarket Shares (%), 2018

Figure 3.10 Pre-Filled Syringe Market Revenue: Submarket Shares (%), 2024

Figure 3.11 Glass Pre-Filled Syringe Submarket: Revenue Forecast ($bn), 2012-2024

Figure 3.12 Glass Pre-Filled Syringe Submarket: Drivers and Restraints, 2014-2024

Figure 3.13 Plastic Pre-Filled Syringe Submarket: Revenue Forecast ($bn), 2012-2024

Figure 3.14 Plastic Pre-Filled Syringe Submarket: Drivers and Restraints, 2014-2024

Figure 3.15 Pen Injector and Autoinjector Submarket: Revenue Forecast ($bn), 2012-2024

Figure 3.16 Pen Injector and Autoinjector Submarket: Drivers and Restraints, 2014-2024

Figure 4.1 Pre-Filled Syringe Market: Revenues ($bn) by Region, 2012-2013

Figure 4.2 Pre-Filled Syringe Market: National Submarket Shares (%), 2018

Figure 4.3 Pre-Filled Syringe Market: National Submarket Shares (%), 2024

Figure 4.4 US Pre-Filled Syringe Submarket Forecast ($bn), 2012-2024

Figure 4.5 French and German Pre-Filled Syringe Submarket Forecasts ($bn), 2012-2024

Figure 4.6 Italian, UK and Spanish Pre-Filled Syringe Submarket Forecasts ($bn), 2012-2024

Figure 4.7 Japanese Pre-Filled Syringe Submarket Forecast ($bn), 2012-2024

Figure 4.8 Chinese Pre-Filled Syringe Submarket Forecast ($bn), 2012-2024

Figure 4.9 Indian Pre-Filled Syringe Submarket Forecast ($bn), 2012-2024

List of Figures

Page 15: Pre filled syringes 2014-2024

www.visiongain.com

Contents Figure 4.10 Brazilian Pre-Filled Syringe Submarket Forecast ($bn), 2012-2024

Figure 4.11 Russian Pre-Filled Syringe Submarket Forecast ($bn), 2012-2024

Figure 5.1 Insulin Market: Revenue Forecast ($bn), 2012-2024

Figure 5.2 Rheumatoid Arthritis Market: Revenue Forecast ($bn), 2012-2024

Figure 5.3 Multiple Sclerosis Market: Revenue Forecast ($bn), 2012-2024

Figure 5.4 Growth Hormone Market: Revenue Forecast ($bn), 2012-2024

Figure 5.5 Heparin Market: Revenue Forecast ($bn), 2012-2024

Figure 5.6 Vaccines Market: Revenue Forecast ($bn), 2012-2024

Figure 6.1 Lantus: Revenue Forecast ($bn), 2012-2024

Figure 6.2 NovoLog: Revenue Forecast ($bn), 2012-2024

Figure 6.3 Humalog: Revenue Forecast ($bn), 2012-2024

Figure 6.4 Humira: Revenue Forecast ($bn), 2012-2024

Figure 6.5 Enbrel: Revenue Forecast ($bn), 2012-2024

Figure 6.6 Copaxone: Revenue Forecast ($bn), 2012-2024

Figure 6.7 Avonex: Revenue Forecast ($bn), 2012-2024

Figure 6.8 Rebif: Revenue Forecast ($bn), 2012-2024

Figure 6.9 Norditropin: Revenue Forecast ($bn), 2012-2024

Figure 6.10 Genotropin: Revenue Forecast ($bn), 2012-2024

Figure 6.11 Lovenox: Revenue Forecast ($bn), 2012-2024

Figure 7.1 Hepatitis B and C: Prevalence by Country, 2013

Figure 7.2 World Biologics Market: Revenue Forecast ($bn), 2012-2024

Figure 7.3 World Biosimilars Market: Revenue Forecast ($bn), 2012-2024

Figure 8.1 BD Medical - Pharmaceutical Systems: Revenue ($bn), 2008-2012

Figure 8.2 Gerresheimer: Revenue ($bn) by Division, 2010-2012

Figure 8.3 Schott: Revenue ($bn), 2011-2012

Figure 8.4 Weigao: Pre-Filled Syringe Revenue ($m) and Production Volume, 2010-2012

Figure 8.5 Unilife: Revenue ($m), 2008-2013

Figure 8.6 Ypsomed Delivery Devices: Revenue ($bn), 2009-2013

Figure 8.7 Owen Mumford: Revenue ($bn), 2009-2012

Figure 8.8 Datwyler Pharma Packaging: Revenue ($bn), 2007-2012

Page 16: Pre filled syringes 2014-2024

www.visiongain.com

Contents Figure 8.9 West Pharmaceutical Services: Revenue ($bn) by Division, 2009-2012

Figure 10.1 Pre-Filled Syringe Market: Revenue Forecast ($bn) by Sector, 2012-2024

Figure 10.2 Pre-Filled Syringe Market: Revenue Forecast ($bn) by Region, 2012-2024

AbbVie

Accu-Chek (part of Roche)

Aché

Aesica Pharmaceuticals

AI Biosciences

Albany Molecular Research Inc (AMRI)

Althea Technologies

Amega Biotech

Amgen

Animas

Antares Pharma

Aptar Pharma (part of AptarGroup)

Aptar Stelmi (part of AptarGroup)

AptarGroup

Batelle

Baxter BioPharma Solutions

Bayer

Becton, Dickinson & Co. (BD)

Berlin-Chemie (part of Menarini Group)

Bespak

Biocon

BioConnection

Biodel

Companies and Other Organisations Mentioned in this Report

Page 17: Pre filled syringes 2014-2024

www.visiongain.com

Contents Biogen Idec

Bioject Medical Technologies

Biosidus

Boehringer Ingelheim

Boehringer Ingelheim BioXcellence (part of Boehringer Ingelheim)

Bristol-Myers Squibb

Cambridge Consultants

Carl Zeiss Foundation

Catalent Pharma Solutions

Centers for Disease Control and Prevention (CDC)

China Food and Drug Administration (CFDA)

Cipla

Consort Medical

Cosmo Pharmaceuticals

Crossject

Daikyo Seiko

DALI Medical Devices

Datwyler

Disetronic Group (part of Roche)

Dong-A Pharmaceutical

Dr. Reddy’s Laboratories

Drug Controller General of India (DCGI)

Duoject Medical Systems

Eisai

Elcam Medical

Eli Lilly

Emisphere

European Medicines Agency (EMA)

FDA Office of Device Evaluation [US]

Ferring Pharmaceuticals

Page 18: Pre filled syringes 2014-2024

www.visiongain.com

Contents Future Injection Technologies (FIT)

Gan & Lee Pharmaceuticals

GAVI Alliance

Genentech (part of Roche)

GeneScience Pharmaceuticals (GenSci)

Gerresheimer

GSK

Haselmeier

Haselmeier Inc. (part of Haselmeier)

Hospira

Hospira One2One (part of Hospira)

Hyaluron Contract Manufacturing (HCM, part of AMRI)

Incepta Pharmaceuticals

Insulet

J&J

Jabil Circuit

Janssen Biotech (part of J&J)

Johns Hopkins University

LG Life Sciences

Marvel Life Sciences

Massachusetts Institute of Technology (MIT)

Medimop Medical Projects (part of West)

Medtronic

Merck & Co.

Merck Serono (part of Merck KGaA)

MG Sterile Products (part of Nipro)

MGlas (part of Nipro)

Ministry of Health, Labor and Welfare (MHLW) [Japan]

Ministry of Labour and Employment [Brazil]

Mitsubishi Tanabe Pharma

Page 19: Pre filled syringes 2014-2024

www.visiongain.com

Contents National Health Service (NHS) [UK]

Nektar Therapeutics

Nipro

Novartis

Novo Nordisk

Nuova Ompi (part of Stevanato Group)

Nypro (part of Jabil Circuit)

Occupational Safety and Health Administration (OSHA) [US]

Optrel (part of Stevanato Group)

Oval Medical

Owen Mumford

PA Consulting Group

PATH

Pfizer

PharmaJet

Pharmstandard

Phillips Medisize

Plastef Investissements

Polfa-Tarchomin

Primequal

Revolutions Medical

Rexam

Roche

Roselabs

Roselabs Bioscience (part of Roselabs)

ROVI CM

Safety Syringes (part of BD)

Sandoz (part of Novartis)

Sanofi

Sanofi Pasteur

Page 20: Pre filled syringes 2014-2024

www.visiongain.com

Contents Savient Pharmaceuticals

Schering-Plough (part of Merck & Co.)

Schott

Schott Kaisha

Schott Xinkang Pharmaceutical Packaging

SciGen

Shanghai Celgen Bio-Pharmaceutical

Shanghai CP Guojian Pharmaceutical

SHL Group

Spami (part of Stevanato Group)

Specialty Coating Systems (SCS)

Square Pharmaceuticals

Stevanato Group

Swedish Orphan Biovitrum (Sobi)

Taisei Kako

Terumo

Teva Pharmaceutical Industries

The Medical House (part of Bespak)

tip-top

Tonghua Dongbao Pharmaceutical

UCB

UNICEF

Unilife

University of Virginia

US Agency for International Development

US Food and Drug Administration (FDA)

Vetter Pharma

Weigao Group

West Pharmaceutical India Packaging Private (part of West)

West Pharmaceutical Services

Page 21: Pre filled syringes 2014-2024

www.visiongain.com

Contents Wockhardt

World Health Organization (WHO)

Wyeth (part of Pfizer)

Ypsomed

Zeon Corporation

Page 22: Pre filled syringes 2014-2024

Page 44

www.visiongain.com

Pre-Filled Syringes: World Industry and Market Prospects 2014-2024

that will challenge pre-filled syringes, pen injectors and autoinjectors in this decade include needle-

free injection systems (considered for the purposes of this report to be a different technology) and

patch injectors. Other administration routes are being assessed for many leading therapies,

including nasal administration for influenza vaccines.

Pre-filled syringes are higher cost to manufacture than vials, which may limit uptake in low-income

countries. Additional cost factors that may restrain growth in emerging markets included the added

storage space required for syringes over vials, which will be a consideration for biological drugs

that must be stored and transported under cold chain conditions.

Two further restraints on growth in the pre-filled syringe market are the development of extended-

release formulations and the number of pipeline projects targeting niche indications with small

patient populations. Both of these factors will reduce demand for pre-filled syringes. For extended-

Pre-filled syringes require increased storage space, resulting in higher cost transportation,

particularly for cold chain products

Oral therapies and other drug delivery technologies will challenge standard injectable

technologies

Smaller drug batches for products targeting niche indications and personalised medicine

Pre-filled syringe units are higher cost to manufacture than vials

Extended-release drugs will lead to less frequent injections and, hence, fewer devices

required

Source: visiongain 2013

Figure 3.8 Pre-Filled Syringes Market: Restraints, 2014-2024

Page 23: Pre filled syringes 2014-2024

Page 66

www.visiongain.com

Pre-Filled Syringes: World Industry and Market Prospects 2014-2024

(etanercept) autoinjector was only launched in Japan in 2013, whereas it was first launched in the

EU in 2005 and in the US in 2006.

Between 2012 and 2024, the Japanese pre-filled syringe submarket will grow with a CAGR of

6.0%, reaching a value of $0.62bn by the end of that period (Table 4.6 and Figure 4.7). Growth will

be driven by uptake of autoinjectors in that submarket, as well as growing use of plastic syringes.

Rising diabetes incidence will drive demand for insulin pens. Demand for new injection systems will

also be driven by the development and launch of new biologics. Companies looking to launch

drugs and devices in Japan after the US will benefit from similar regulatory requirements for

combination products. Biosimilars will be less of a growth driver here than in the US and EU, we

believe. Although follow-on drug use has grown dramatically in recent years in Japan, it still

remains below levels in other developed markets. Biosimilars will have a similar impact in this

submarket.

0.30

0.35

0.40

0.45

0.50

0.55

0.60

0.65

2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

Subm

arke

t Si

ze ($

bn)

Year

Figure 4.7 Japanese Pre-Filled Syringe Submarket Forecast ($bn), 2012-2024

Source: visiongain 2013

Page 24: Pre filled syringes 2014-2024

Page 169

www.visiongain.com

Pre-Filled Syringes: World Industry and Market Prospects 2014-2024

8.1.6.3 Roselabs Entered the Market in 2012 Roselabs Bioscience, part of the Roselabs Group, is the newest manufacturer of pre-filled syringes

in the market. That company opened its manufacturing facility in India at the end of 2012, investing

more than $70m in this new sector. The company reports that its new manufacturing facility is

capable of producing 800,000 syringes per day. It manufactures both glass and plastic pre-filled

syringes. The company reported plans to open a plant manufacturing more than 150 million pre-

filled syringes per year. However, Roselabs is not just manufacturing and selling ready-to-fill

syringes. Like BD, the company has launched a range of generic injectables in its pre-filled

syringes. The company is targeting emerging markets in Asia and Latin America for sales of these

products. In August 2013, Roselabs announced a marketing agreement with an unnamed Brazilian

company to launch the range of injectables in that market.

0

5

10

15

20

25

2008 2009 2010 2011 2012 2013

Rev

enue

($m

)

Year

2008 2009 2010 2011 2012 2013

Revenue ($m) 4 20 11 7 6 3

Annual Growth (%) 471 -43 -42 -17 -50

CAGR (%) -4.8

Table 8.7 Unilife: Revenue ($m), 2008-2013

Source: Unilife annual reports 2013, visiongain 2013

Figure 8.5 Unilife: Revenue ($m), 2008-2013

Source: Unilife annual reports 2013, visiongain 2013